Marketed by Lilly under license from Incyte (INCY), the product belongs to a class of drugs known as JAK inhibitors, where its sales run a distant second to those of Xeljanz from Pfizer (PFE).“We are working with a speed that I have never, ever experienced in the past.” Big pharma companies like Lilly have enjoyed renewed popularity on Wall Street as the public has shifted toward seeing the industry as delivering humankind from the pandemic, as opposed to being a driver of health care spending inflation.